Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00764517 · ClinicalTrials.gov registry record · Phase 2
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00764517 is a Phase 2 study that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 57 participants.
The verdict
NCT00764517, a Phase 2 study, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving vorinostat, cladribine, and rituximab together works in treating patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or B cell non-Hodgkin's lymphoma (NHL) that has returned after a period of improvement. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving vorinostat together with cladribine and rituximab may kill more cancer cells.
Interventions
- DRUG Cladribine
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Rituximab
- DRUG Vorinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2008-08 |
| Est. Completion | 2017-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00764517
The ClinicalTrials.gov registry entry for NCT00764517 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cladribine is the first listed.
NCT00764517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00764517 about?
NCT00764517 is a clinical study titled "Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma". This phase II trial studies how well giving vorinostat, cladribine, and rituximab together works in treating patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or B cell non-Hodgkin's lymphoma (NHL) that has returned after a period of improvement. Vorinostat may stop the g...
What is the current status of trial NCT00764517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2008-08. Estimated completion is 2017-03.
What interventions are being tested in trial NCT00764517?
The interventions under investigation include: Cladribine (DRUG), Laboratory Biomarker Analysis (OTHER), Rituximab (BIOLOGICAL), Vorinostat (DRUG).
Who is sponsoring clinical trial NCT00764517?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.